KAISER PERMANENTE®

Northwest Region Utilization Review

UR 72: CPAP Titration in a Sleep Center Medical Necessity Criteria

Department: Non-Behavioral Health Section: KPNW Region Applies to: KPNW Region Review Responsibility: Yanina Benikova, MD Number: UR 72 Effective: 01/2020 Last Reviewed/Approved: 1/23, 1/30/24

CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) TITRATION IN A SLEEP CENTER MEDICAL NECESSITY CRITERIA

For Medicare Members	
Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations	None
(NCD)	
Local Coverage Determinations (LCD)	L34040 "Polysomnography and Other Sleep Studies"
Local Coverage Article	A57698 "Billing and Coding: Polysomnography and
	Other Sleep Studies"
Kaiser Permanente Medical Policy	For Medicare members, follow the criteria in the LCD.

POLICY AND CRITERIA

For Non-Medicare Members

CPAP sleep center titration may be indicated for **1 or more** of the following:

- 1) Adult with central sleep apnea syndrome due to congestive heart failure
- 2) Adult with obesity hypoventilation (shallow breathing) syndrome, as indicated by **ALL** of the following
 - A. BMI (body mass index) greater than 30
 - B. Daytime hypercapnia (excess carbon dioxide in the blood) with PaCO₂ (partial pressure of carbon dioxide) greater than 45 mm Hg/ 6.0 kPa (kPa is a unit of pressure) without other etiology (eg, kyphoscoliosis, lung parenchymal disease, myopathy, severe hypothyroidism)
 - C. Sleep-disordered breathing or hypoventilation on polysomnography (sleep study), as indicated by **1 or more** of the following:
 - i. Apnea-hypopnea index of 5 or greater
 - ii. Increase in $PaCO_2$ during sleep by more than 10 mm Hg/ 1.3 kPa above value while awake
 - iii. Significant oxygen desaturation (ie, less than 90%) not explained by obstructive apneas or hypopneas
 - D. TSH level does not demonstrate hypothyroidism.
- 3) Adult with obstructive sleep apnea, as indicated by **ALL** of the following:
 - A. Appropriate testing situation, as indicated by **1 or more** of the following:
 - i. Initial full-night CPAP titration study

- ii. Repeat full-night CPAP titration study, as indicated by **1 or more** of the following:
 - a. Greater than 10% body weight gain or loss, and need to adjust pressure settings
 - b. Inadequate initial CPAP titration study, and need to perform further pressure titration
 - c. Insufficient response to CPAP therapy due to inadequate pressure or pressure leaks
 - d. Return of symptoms after initial adequate response to CPAP therapy, and need to adjust pressure settings
- B. Obstructive sleep apnea, as indicated by **1 or more** of the following:
 - Mild obstructive sleep apnea (ie, apnea-hypopnea index or respiratory disturbance index between 5 and 15, determined with polysomnography) and 1 or more of the following:
 - a. Cardiovascular disease documented (eg, hypertension, ischemic heart disease, heart failure, stroke)
 - b. Excessive daytime sleepiness (eg, Epworth Sleepiness Scale score of 10 or greater in adult patient)
 - c. Fibromyalgia-like symptoms
 - d. Headaches upon awakening
 - e. Heartburn and reflux
 - f. Impaired cognition
 - g. Mood disorder
 - h. Night sweats
 - i. Nocturia or nocturnal enuresis
 - j. Observed apnea or choking episodes
 - k. Patient is commercial vehicle driver
 - I. Snoring
 - ii. Moderate or severe obstructive sleep apnea (ie, apnea-hypopnea index or respiratory disturbance index 15 or greater, determined with polysomnography)
 - iii. Upper airway resistance syndrome associated with unexplained excessive daytime sleepiness
- C. Performed as full-night CPAP titration study
- 4) Child, infant, or adolescent with obstructive sleep apnea and **ALL** of the following:
 - A. Appropriate testing situation, as indicated by **1 or more** of the following:
 - i. Initial full-night CPAP titration study
 - ii. Repeat full-night CPAP titration study, as indicated by **1 or more** of the following:
 - a. Greater than 10% body weight gain or loss, and need to adjust pressure settings
 - b. Inadequate initial CPAP titration study, and need to perform further pressure titration
 - c. Insufficient response to CPAP therapy due to inadequate pressure or pressure leaks
 - d. Return of symptoms after initial adequate response to CPAP therapy, and need to adjust pressure settings
 - B. Polysomnography demonstrates obstructive sleep apnea (ie, apnea-hypopnea index of 1 or greater in child younger than 18 years)

- C. Signs and symptoms consistent with obstructive sleep apnea, including **1 or more** of the following:
 - i. Daytime sleepiness
 - ii. Enuresis
 - iii. Failure to thrive (weight less than fifth percentile for age)
 - iv. Hyponasal speech
 - v. Mouth breathing
 - vi. Nocturnal pauses in breathing
 - vii. Nonspecific behavioral problems (eg, hyperactivity, developmental delay, aggression, poor school performance)
 - viii. Pulmonary hypertension
 - ix. Signs of increased respiratory effort (ie, nasal flaring)
 - x. Snoring
- D. No tonsillar or adenoid enlargement (or tonsillar or adenoid enlargement and contraindication to surgical intervention), or failure of tonsil or adenoid removal to change symptoms
- E. Performed as full-night CPAP titration study

RATIONALE

EVIDENCE BASIS

MCG reviewed the evidence on CPAP in 2022.¹ Their findings are provided below:

"For adults with central sleep apnea due to congestive heart failure, evidence demonstrates at least moderate certainty of at least moderate net benefit. A systematic review identified 16 articles that studied treatment of central sleep apnea syndromes related to congestive heart failure and concluded that CPAP therapy can normalize the apnea-hypopnea index and improve left ventricular ejection fraction.²

For adults with obesity hypoventilation syndrome, evidence demonstrates at least moderate certainty of at least moderate net benefit. CPAP has been shown to be effective for the treatment of the majority of patients with obesity hypoventilation syndrome, particularly in the subgroup with severe obstructive sleep apnea.³

For adults with obstructive sleep apnea, evidence demonstrates at least moderate certainty of at least moderate net benefit. In adults, mild obstructive sleep apnea is defined as an apnea-hypopnea index or respiratory disturbance index of 5 to 15, moderate as 15 to 30, and severe as greater than 30.⁴ Systematic reviews, prospective cohort studies, and randomized trials have concluded that CPAP is an effective treatment, with improvement in objective and subjective sleepiness, quality of life, and clinical measures such as blood pressure (in patients who are hypertensive) and cardiovascular mortality.⁵⁻⁹ A randomized trial evaluating the effects of CPAP on prehypertension and masked hypertension in males with severe obstructive sleep apnea found that the use of CPAP promotes significant reductions in blood pressure.¹⁰ Another randomized trial of male and female patients with resistant hypertension and obstructive sleep apnea found that the use of CPAP for greater than 5.8 hours at a time resulted in significant blood pressure reductions.¹¹ For patients with obstructive sleep apnea and heart failure, studies have demonstrated improved left ventricular ejection fraction and cardiac remodeling, and a trend toward decreased mortality when treatment consists of CPAP in addition to optimal medical therapy for heart failure.¹²⁻¹⁴ A study of nocturnal CPAP in obese patients

with obstructive sleep apnea found that the use of CPAP increased exercise tolerance and improved dyspnea in these patients.¹⁵ With appropriate titration, positive airway pressure devices resolve most sleep-disordered breathing regardless of the disease severity level;¹⁶ goals of CPAP titration include achieving a respiratory disturbance index less than 5, a pulse oximetry greater than 90%, and tolerable air leak at the mask.¹⁷ Performance of a split-night study may be indicated if the diagnosis of moderate or severe obstructive sleep apnea can be made within the first 2 hours of recorded sleep, and at least 3 hours of CPAP titration is demonstrated, including the ability of CPAP to eliminate respiratory events during both rapid eye movement sleep and non-rapid eye movement sleep.^{18, 19} Specialty society practice parameters note that a repeat CPAP titration study may be appropriate when the initial CPAP titration fails to resolve obstructive sleep apnea findings sufficiently, when the response to therapy is inadequate despite good adherence and adequate interface fit, when symptoms return after a period of adequate response to CPAP therapy, or when greater than 10% body weight gain or loss necessitates adjustment of pressure settings.^{20, 21}

For children, infants, or adolescents with obstructive sleep apnea, evidence demonstrates at least moderate certainty of at least moderate net benefit. The criteria for interpreting pediatric polysomnograms typically define mild obstructive sleep apnea as an apnea-hypopnea index of 1 to 5, moderate as 6 to 10, and severe as greater than 10.²²⁻²⁴ A specialty society recommended using the pediatric scoring rules for children younger than 18 years of age; however, studies indicated that some of the adult scoring rules may be used in adolescents 13 to 18 years of age.²⁵⁻²⁹ Specialty society clinical guidelines recommend that pediatric patients with symptoms of obstructive sleep apnea who are not candidates for adenotonsillectomy or who have persistent obstructive sleep apnea after adenotonsillectomy should be referred for CPAP management.^{24, 30, 31} Although there is limited evidence for its use, a specialty society recommends using polysomnography when titrating CPAP in infants.³² Performance of a split-night study may be indicated if the diagnosis of moderate or severe obstructive sleep apnea can be made within the first 2 hours of recorded sleep, and at least 3 hours of CPAP titration is demonstrated, including the ability of CPAP to eliminate respiratory events during both rapid eve movement sleep and non-rapid eve movement sleep.^{18, 19} An evidence-based specialty society guideline is unable to recommend split-night CPAP titration for children younger than 12 years due to a lack of data.²⁰ A review article noted that obstructive sleep apnea in children may manifest as hyperactivity, emotional difficulties, decreased academic performance, and difficulty concentrating; in contrast, daytime sleepiness, morning headache, memory impairment, and daytime fatigue are more common symptoms in adults.³³ Specialty society guidelines note that repeat CPAP titration testing may be appropriate when the initial CPAP titration study fails to achieve optimal results, when symptoms return after an initial adequate CPAP therapy response, after 10% body weight gain or loss, and with growth in children using CPAP therapy for obstructive sleep apnea.^{20, 24, 31}"1

The United States Preventive Services Task Force (USPSTF) issued updated recommendations on screening for obstructive sleep apnea in asymptomatic adults in November 2022.³⁴ The supporting evidence review examined the benefits, effectiveness, and harms of treatment with positive airway pressure in adults with obstructive sleep apnea and reports that, compared to inactive control, positive airway pressure was associated with a significant improvement in Epworth Sleepiness Scale score from baseline, sleep-related quality of life, and general health-related quality of life.³⁴ Additionally, the review summarizes evidence from other systematic reviews that show a small but statistically significant association of positive airway pressure with reduced blood pressure.³⁴ No included trials in this review

found significant benefits of treatment with positive airway pressure on mortality, cardiovascular events, or motor vehicle crashes.³⁴

REFERENCES

1. MCG. CPAP Titration, Sleep Center. MCG. Accessed December 5, 2022.

2. Aurora RN, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep*. Jan 1 2012;35(1):17-40. doi:10.5665/sleep.1580

3. Piper AJ, Wang D, Yee BJ, Barnes DJ, Grunstein RR. Randomised trial of CPAP vs bilevel support in the treatment of obesity hypoventilation syndrome without severe nocturnal desaturation. *Thorax*. May 2008;63(5):395-401. doi:10.1136/thx.2007.081315

4. Kimoff RJ, Kaminska M, Pamidi S. Obstructive sleep apnea. In: Broaddus VC, ea, eds. *Murray & Nadel's Textbook of Respiratory Medicine*. 7th ed. ed. Elsevier Saunders; 2022:1654-1669.

5. McDaid C, Griffin S, Weatherly H, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. *Health Technol Assess*. Jan 2009;13(4):iii-iv, xi-xiv, 1-119, 143-274. doi:10.3310/hta13040

6. Tomfohr LM, Ancoli-Israel S, Loredo JS, Dimsdale JE. Effects of continuous positive airway pressure on fatigue and sleepiness in patients with obstructive sleep apnea: data from a randomized controlled trial. *Sleep*. Jan 1 2011;34(1):121-6. doi:10.1093/sleep/34.1.121

7. Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. *Ann Intern Med.* Jan 17 2012;156(2):115-22. doi:10.7326/0003-4819-156-2-201201170-00006

8. Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. *Jama*. May 23 2012;307(20):2169-76. doi:10.1001/jama.2012.3418

9. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. *J Clin Sleep Med*. Feb 15 2019;15(2):301-334. doi:10.5664/jcsm.7638

10. Drager LF, Pedrosa RP, Diniz PM, et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. *Hypertension*. Mar 2011;57(3):549-55. doi:10.1161/hypertensionaha.110.165969

11. Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. *J Hypertens*. Oct 2010;28(10):2161-8. doi:10.1097/HJH.0b013e32833b9c63

12. Egea CJ, Aizpuru F, Pinto JA, et al. Cardiac function after CPAP therapy in patients with chronic heart failure and sleep apnea: a multicenter study. *Sleep Med.* Aug 2008;9(6):660-6. doi:10.1016/j.sleep.2007.06.018

13. Kasai T, Narui K, Dohi T, et al. Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. *Chest*. Mar 2008;133(3):690-6. doi:10.1378/chest.07-1901

14. Colish J, Walker JR, Elmayergi N, et al. Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. *Chest.* Mar 2012;141(3):674-681. doi:10.1378/chest.11-0615

15. Pendharkar SR, Tsai WH, Eves ND, Ford GT, Davidson WJ. CPAP increases exercise tolerance in obese subjects with obstructive sleep apnea. *Respir Med*. Oct 2011;105(10):1565-71. doi:10.1016/j.rmed.2011.06.007

16. Freedman N. Treatment of Obstructive Sleep Apnea: Choosing the Best Positive Airway Pressure Device. *Sleep Med Clin*. Dec 2017;12(4):529-542. doi:10.1016/j.jsmc.2017.07.003

17. Weiss P, Kryger M. Positive Airway Pressure Therapy for Obstructive Sleep Apnea. *Otolaryngol Clin North Am*. Dec 2016;49(6):1331-1341. doi:10.1016/j.otc.2016.07.004

18. Patel NP, Ahmed M, Rosen I. Split-night polysomnography. *Chest*. Nov 2007;132(5):1664-71. doi:10.1378/chest.06-1801

19. Khawaja IS, Olson EJ, van der Walt C, et al. Diagnostic accuracy of split-night polysomnograms. *J Clin Sleep Med*. Aug 15 2010;6(4):357-62.

20. Kushida CA, Chediak A, Berry RB, et al. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. *J Clin Sleep Med*. Apr 15 2008;4(2):157-71.

21. Epstein LJ, Kristo D, Strollo PJ, Jr., et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. Jun 15 2009;5(3):263-76.

22. Goldstein NA. Evaluation and management of pediatric obstructive sleep apnea. In: Flint PW, ea, eds. *Cummings Otolaryngology Head and Neck Surgery*. 7th ed. ed. Elsevier; 2021:2798-2807.

23. Shangold L. How to Evaluate a Diagnostic Sleep Study Report. *Otolaryngol Clin North Am*. Dec 2016;49(6):1307-1329. doi:10.1016/j.otc.2016.07.003

24. Kaditis AG, Alonso Alvarez ML, Boudewyns A, et al. Obstructive sleep disordered breathing in 2to 18-year-old children: diagnosis and management. *Eur Respir J*. Jan 2016;47(1):69-94. doi:10.1183/13993003.00385-2015

25. Berry RB, Albertario CL, Harding SM, et al. *The AASM Manual for the Scoring of Sleep and Associated Events*. 2.5 ed. ed. American Academy of Sleep Medicine; 2018.

26. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med.* Oct 15 2012;8(5):597-619. doi:10.5664/jcsm.2172

27. Accardo JA, Shults J, Leonard MB, Traylor J, Marcus CL. Differences in overnight polysomnography scores using the adult and pediatric criteria for respiratory events in adolescents. *Sleep.* Oct 2010;33(10):1333-9. doi:10.1093/sleep/33.10.1333

28. Tapia IE, Karamessinis L, Bandla P, et al. Polysomnographic values in children undergoing puberty: pediatric vs. adult respiratory rules in adolescents. *Sleep*. Dec 2008;31(12):1737-44. doi:10.1093/sleep/31.12.1737

29. Grigg-Damberger MM. The AASM Scoring Manual four years later. *J Clin Sleep Med*. Jun 15 2012;8(3):323-32. doi:10.5664/jcsm.1928

30. Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics*. Sep 2012;130(3):576-84. doi:10.1542/peds.2012-1671

31. Aurora RN, Zak RS, Karippot A, et al. Practice parameters for the respiratory indications for polysomnography in children. *Sleep*. Mar 1 2011;34(3):379-88. doi:10.1093/sleep/34.3.379

32. Wise MS, Nichols CD, Grigg-Damberger MM, et al. Executive summary of respiratory indications for polysomnography in children: an evidence-based review. *Sleep*. Mar 1 2011;34(3):389-98aw. doi:10.1093/sleep/34.3.389

33. Alsubie HS, BaHammam AS. Obstructive Sleep Apnoea: Children are not little Adults. *Paediatr Respir Rev.* Jan 2017;21:72-79. doi:10.1016/j.prrv.2016.02.003

34. Feltner C, Wallace IF, Aymes S, et al. Screening for Obstructive Sleep Apnea in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*. Nov 15 2022;328(19):1951-1971. doi:10.1001/jama.2022.18357